Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment.
about
Biological markers of amyloid beta-related mechanisms in Alzheimer's diseaseExpanding the Repertoire of Biomarkers for Alzheimer's Disease: Targeted and Non-targeted ApproachesA window into the heterogeneity of human cerebrospinal fluid Aβ peptidesStructures of Aβ-Related Peptide−Monoclonal Antibody Complexes ,Biomarkers in the diagnosis of Alzheimer's disease: are we ready?Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient.Distinct glutaminyl cyclase expression in Edinger-Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Abeta pathology in Alzheimer's disease.Characterization of cerebrospinal fluid aminoterminally truncated and oxidized amyloid-β peptides.Anti-11[E]-pyroglutamate-modified amyloid β antibodies cross-react with other pathological Aβ species: relevance for immunotherapy.CSF beta-amyloid 1-42 - what are we measuring in Alzheimer's disease?A novel mutation P112H in the TARDBP gene associated with frontotemporal lobar degeneration without motor neuron disease and abundant neuritic amyloid plaquesBeta-amyloid peptide variants in brains and cerebrospinal fluid from amyloid precursor protein (APP) transgenic mice: comparison with human Alzheimer amyloid.Magnetic resonance spectroscopy in the prediction of early conversion from amnestic mild cognitive impairment to dementia: a prospective cohort study.Neurochemical biomarkers in Alzheimer's disease and related disorders.Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer's, but not in frontotemporal dementiaClinical proteomics in neurodegenerative disorders.Biomarkers for early diagnosis of Alzheimer disease: 'ALZheimer ASsociated gene'--a new blood biomarker?Targeted proteomics in Alzheimer's disease: focus on amyloid-beta.Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid Aβ42 and the Ratios of Aβ Isoforms Using Low Protein Binding Tubes.Immunodominant epitope and properties of pyroglutamate-modified Abeta-specific antibodies produced in rabbitsUpdate on amyloid-beta homeostasis markers for sporadic Alzheimer's disease.Plasma amyloid-β levels and prognosis in incident dementia cases of the 3-City StudyAspects of beta-amyloid as a biomarker for Alzheimer's disease.Cerebrospinal fluid biomarkers for Alzheimer's disease: the present and the future.Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy.Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.Alternative Selection of β-Site APP-Cleaving Enzyme 1 (BACE1) Cleavage Sites in Amyloid β-Protein Precursor (APP) Harboring Protective and Pathogenic Mutations within the Aβ Sequence.Structural design, solid-phase synthesis and activity of membrane-anchored β-secretase inhibitors on Aβ generation from wild-type and Swedish-mutant APP.Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid β-peptide.Performance Evaluation of an Automated ELISA System for Alzheimer's Disease Detection in Clinical Routine.Neuropsychological markers of progression from mild cognitive impairment to Alzheimer's disease.Characterization of AβpN3 deposition in the brains of dogs of various ages and other animal species.Preoperative Phosphorylated Tau Concentration in the Cerebrospinal Fluid Can Predict Cognitive Function Three Years after Shunt Surgery in Patients with Idiopathic Normal Pressure Hydrocephalus
P2860
Q24622136-4F8AE6C8-BB99-4A9F-808C-E5407CB2D3E4Q26770708-7C83CD8C-F77C-4C30-8967-F733CC6ED060Q27010785-5298311E-4ACB-414E-A90B-6D23E885BAC6Q27655072-CE008452-F3D6-4457-83A7-95D7EDD7FAA6Q31050728-A49F447F-019E-4B8A-AF0F-3BB6E308AAE9Q33801986-3B4BF15A-1F9C-485C-9BE9-1ADEB2CEA957Q33942884-418DA7AC-144C-418C-8102-D31E86A858C3Q34244772-91005B73-9DAD-4C04-B3CB-755166277360Q34348316-B7EFC0F3-C4C7-4F69-8A99-D11277E71A73Q35115904-F6B0DE20-E56A-42E4-897E-FE2A0AD30ED7Q35246500-A893EAFC-289D-4A14-A443-891FDFA25D94Q35311113-C98BA618-CB3F-4EFD-BDAB-5C183E0A94DEQ35319467-9C5AFED6-726E-42BD-96B5-EAC5ABDC395CQ36366891-50AE1980-1002-48CA-876D-BBF94F2B60CDQ36708123-3F25AD59-F20E-4264-8F34-BD7264596C1CQ37086170-2B6FD117-29DF-4878-99B9-A7BD7CDE2739Q37118083-AC70F248-9AD0-4DB4-A388-D820C548ED6BQ37157835-EF317B6F-7595-4072-9E1F-D8EEDE881C15Q37169132-A45CC343-CED2-41F4-9694-64EDF1590CB8Q37301151-22EBF938-7D60-4004-AE7A-4199A2F5C266Q37387103-E78227F8-3125-4DAF-A8CC-7EB5BC9D92A0Q37693190-778266AB-0027-4F3F-BFB3-5935924F4FB4Q37755129-DB6B36EF-2ABD-4EFC-92F6-7FAC340FF54DQ37895052-2329FBE0-3339-4979-9A98-D59BE92A4D3FQ38176899-CD8C61F3-514E-47FF-967B-76430A5A8431Q38289739-13AC5122-152F-4A02-9D15-21B3C06BCDD5Q38743102-28C4D5EB-514A-4D4F-9CF5-80AA68EA416AQ42785839-88B58C47-2828-4B1C-BD1D-377DEE59DF79Q44640299-EAADE640-D4B6-47B1-8472-B23F0C8C3306Q47976273-0E70D78C-FB54-4BF3-8E66-9F11DA307720Q51980686-A66CB7FB-6039-479D-9D9C-674EC3C1E023Q53318965-3F768CE1-A57C-4F4A-B399-FEBAAA7CDFC6Q58730162-5A6A0772-348F-4500-B2A5-761E2342FAFE
P2860
Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment.
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Amino-truncated beta-amyloid42 ...... of mild cognitive impairment.
@ast
Amino-truncated beta-amyloid42 ...... of mild cognitive impairment.
@en
type
label
Amino-truncated beta-amyloid42 ...... of mild cognitive impairment.
@ast
Amino-truncated beta-amyloid42 ...... of mild cognitive impairment.
@en
prefLabel
Amino-truncated beta-amyloid42 ...... of mild cognitive impairment.
@ast
Amino-truncated beta-amyloid42 ...... of mild cognitive impairment.
@en
P2093
P1433
P1476
Amino-truncated beta-amyloid42 ...... of mild cognitive impairment.
@en
P2093
Anders Wallin
Annika Olsson
Geert De Meyer
Hugo Vanderstichele
Niels Andreasen
Vesna Kostanjevecki
P304
P356
10.1373/CLINCHEM.2005.051201
P407
P577
2005-07-14T00:00:00Z